PET imaging in breast cancer.

摘要: The basis of tumour imaging with PET is a specific uptake mechanism positron emitting radiopharmaceuticals. Among the potential tracers for breast cancer (fluorodeoxyglucose, methionine, tyrosine, fluoro-estradiol, nor-progesterone), 2-deoxy-2-fluoro-D-glucose labelled fluorine (FDG) most widely used radiopharmaceutical because particularly avid FDG and 18F has advantages relatively long physical half-life. Mammography first choice examination in studying masses, due to its very good performances, an excellent compliance best value regarding cost/effectiveness aspects. However FDG-PET revealed be effective study patients ambiguous mammographies. tissue correlates histological grade aggressiveness this may have prognostic consequences. Besides evaluation lesions, shows great efficacy staging lymph node involvement prior surgery could loco-regional staging. Whole body provides also information regard metastasis localizations both soft bone, plays important clinical role mainly detecting recurrent metastatic disease. In fact metabolic characteristics visualizes regions enhanced activity can complements other modalities based on structural anatomic changes. Even though CT MRI show superior resolution characteristics, it been demonstrated that more accurate discriminating between viable tumour, fibrotic scar or necrosis. Several evidences able predict wether will respond therapy, or, when applied at end treatment, assess response therapy. These statements are coming from than 2000 included 88 articles abstracts studies which was detection.